X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs IPCA LABS - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD IPCA LABS MERCK LTD/
IPCA LABS
 
P/E (TTM) x 44.1 29.6 149.0% View Chart
P/BV x 6.4 3.8 170.7% View Chart
Dividend Yield % 0.5 0.1 423.9%  

Financials

 MERCK LTD   IPCA LABS
EQUITY SHARE DATA
    MERCK LTD
Dec-17
IPCA LABS
Mar-18
MERCK LTD/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,358695 195.2%   
Low Rs933400 233.3%   
Sales per share (Unadj.) Rs665.0260.2 255.6%  
Earnings per share (Unadj.) Rs56.619.0 298.2%  
Cash flow per share (Unadj.) Rs72.533.1 219.3%  
Dividends per share (Unadj.) Rs15.001.00 1,500.0%  
Dividend yield (eoy) %1.30.2 717.4%  
Book value per share (Unadj.) Rs441.7213.0 207.3%  
Shares outstanding (eoy) m16.60126.20 13.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.72.1 81.8%   
Avg P/E ratio x20.228.9 70.1%  
P/CF ratio (eoy) x15.816.6 95.4%  
Price / Book Value ratio x2.62.6 100.8%  
Dividend payout %26.55.3 503.0%   
Avg Mkt Cap Rs m19,01169,120 27.5%   
No. of employees `0001.513.3 11.6%   
Total wages/salary Rs m1,6967,359 23.1%   
Avg. sales/employee Rs Th7,150.02,477.4 288.6%   
Avg. wages/employee Rs Th1,098.7555.2 197.9%   
Avg. net profit/employee Rs Th608.2180.6 336.7%   
INCOME DATA
Net Sales Rs m11,04032,836 33.6%  
Other income Rs m240418 57.3%   
Total revenues Rs m11,27933,254 33.9%   
Gross profit Rs m1,3764,505 30.5%  
Depreciation Rs m2641,777 14.9%   
Interest Rs m0240 0.0%   
Profit before tax Rs m1,3522,905 46.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1700-   
Tax Rs m583511 114.0%   
Profit after tax Rs m9392,394 39.2%  
Gross profit margin %12.513.7 90.9%  
Effective tax rate %43.117.6 245.1%   
Net profit margin %8.57.3 116.7%  
BALANCE SHEET DATA
Current assets Rs m7,52319,455 38.7%   
Current liabilities Rs m2,25310,076 22.4%   
Net working cap to sales %47.728.6 167.1%  
Current ratio x3.31.9 173.0%  
Inventory Days Days5298 53.3%  
Debtors Days Days4167 60.6%  
Net fixed assets Rs m1,24020,260 6.1%   
Share capital Rs m166252 65.8%   
"Free" reserves Rs m7,16726,633 26.9%   
Net worth Rs m7,33326,886 27.3%   
Long term debt Rs m02,340 0.0%   
Total assets Rs m9,91241,173 24.1%  
Interest coverage xNM13.1-  
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.10.8 139.7%   
Return on assets %9.56.4 148.1%  
Return on equity %12.88.9 143.8%  
Return on capital %20.810.8 192.8%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m1,01515,642 6.5%   
Fx outflow Rs m3,0434,884 62.3%   
Net fx Rs m-2,02810,759 -18.9%   
CASH FLOW
From Operations Rs m5373,411 15.7%  
From Investments Rs m-476-1,354 35.2%  
From Financial Activity Rs m-220-1,304 16.9%  
Net Cashflow Rs m-160753 -21.2%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 11.4 159.6%  
FIIs % 1.0 25.3 4.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 17.4 167.2%  
Shareholders   28,591 36,892 77.5%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   FDC LTD.  FULFORD INDIA  WYETH LTD  AJANTA PHARMA  UNICHEM LAB  

Compare MERCK LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 150 Points Higher; Banking Stocks Witness Buying(Closing)

Indian share markets continued their momentum and ended the day on a positive note. Gains were largely seen in the banking sector, consumer durables sector and realty sector.

Related Views on News

IPCA LABS at 52 Week High; BSE 500 Index Up 1.0% (Market Updates)

Dec 13, 2018 | Updated on Dec 13, 2018

IPCA LABS share price has hit a 52-week high. It is presently trading at Rs 824. BSE 500 Index is up by 0.7% at 14,435. Within the BSE 500, IPCA LABS (up 3.4%) and UJJIVAN FINANCIAL SERVICES (up 9.5%) are among the top gainers, while top losers are MANPASAND BEVERAGES and KWALITY DAIRY.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Dec 13, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MERCK LTD - SHASUN PHARMA COMPARISON

COMPARE MERCK LTD WITH

MARKET STATS